Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In Multiple Myeloma

4/29/24 9:39:46 AM ET

$IMMX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IMMX alert in real time by email

European Orphan Drug Designation ("ODD") qualifies NXC-201 for:

10 years of market exclusivity once authorized in the EU
Access to the EU centralized authorization procedure
- Reduced fees for: EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees

Get the next $IMMX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMMX

Date	Price Target	Rating	Analyst

More analyst ratings

$IMMX
Press Releases

Fastest customizable press release news feed in the world

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. Comenzo was the lead author on the landmark 2012 publication of consensus guidelines, including response criteria, for conduct and reporting of clinical trials in AL Amyloidosis LOS ANGELES, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX), announced that effective today, Dr. Raymond Comenzo, internationally recognized AL Amyloidosis expert and Director of the Myeloma and Amyloid Program at Tufts Medi
9/19/24 9:31:00 AM ET
$IMMX
Biotechnology: Pharmaceutical Preparations
Health Care
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum. Stifel 2024 Cell Therapy Forum - Immix Biopharma Date:Tuesday, July 9, 2024Presentation: Immix Biopharma to presentLocation:VirtualInvestor Meetings:The IMMX Team will be available for institutional investor meetings during the conference. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company
6/17/24 9:35:00 AM ET
$IMMX
Biotechnology: Pharmaceutical Preparations
Health Care
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA
6/10/24 8:30:00 AM ET
$IMMX
$RNXT
Biotechnology: Pharmaceutical Preparations
Health Care

$IMMX
Leadership Updates

Live Leadership Updates

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. Comenzo was the lead author on the landmark 2012 publication of consensus guidelines, including response criteria, for conduct and reporting of clinical trials in AL Amyloidosis LOS ANGELES, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX), announced that effective today, Dr. Raymond Comenzo, internationally recognized AL Amyloidosis expert and Director of the Myeloma and Amyloid Program at Tufts Medi
9/19/24 9:31:00 AM ET
$IMMX
Biotechnology: Pharmaceutical Preparations
Health Care
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA
6/10/24 8:30:00 AM ET
$IMMX
$RNXT
Biotechnology: Pharmaceutical Preparations
Health Care
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board. Dr. Sanchorawala is internationally recognized for her pioneering work in development of novel agents to treat AL Amyloidosis, including the establishment of daratumumab as the standard of care. "Therapeutic landscape of AL amyloidosis is evolving. There is a marked progress in survival of patients with AL amyloidosis. However, better and more effective therapies are needed for those relapsing after Daratumumab based treatments. I am
1/4/24 9:34:00 AM ET
$IMMX
Biotechnology: Pharmaceutical Preparations
Health Care

Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In Multiple Myeloma

Chat with this insight

Recent Analyst Ratings for
$IMMX

$IMMX
Insider purchases explained

Analytical look into recent insider purchases

Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

$IMMX
Press Releases

Fastest customizable press release news feed in the world

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

$IMMX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$IMMX
SEC Filings

SEC Form SC 13G filed by Immix Biopharma Inc.

SEC Form SC 13D filed by Immix Biopharma Inc.

SEC Form SC 13G/A filed by Immix Biopharma Inc. (Amendment)

SEC Form 10-Q filed by Immix Biopharma Inc.

Immix Biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Immix Biopharma Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

$IMMX
Leadership Updates

Live Leadership Updates

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

$IMMX
Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target

Immix Biopharma Doses First Patient In U.S. AL Amyloidosis Trial With CAR-T NXC-201; Data From ex-US Clinical Trial Reported At ASGCT 2024 Showed A 92% Overall Response Rate

HC Wainwright & Co. Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $7

$IMMX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Hsu Jason bought $51,623 worth of shares (23,100 units at $2.23), increasing direct ownership by 3% to 845,300 units (SEC Form 4)

Director Ng Carey bought $18,600 worth of shares (10,000 units at $1.86), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

Director Hsu Jason bought $19,517 worth of shares (9,200 units at $2.12), increasing direct ownership by 1% to 822,200 units (SEC Form 4)

$IMMX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Hsu Jason bought $51,623 worth of shares (23,100 units at $2.23), increasing direct ownership by 3% to 845,300 units (SEC Form 4)

Director Ng Carey bought $18,600 worth of shares (10,000 units at $1.86), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

Director Hsu Jason bought $19,517 worth of shares (9,200 units at $2.12), increasing direct ownership by 1% to 822,200 units (SEC Form 4)

Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In Multiple Myeloma

Chat with this insight

Recent Analyst Ratings for $IMMX

$IMMX Insider purchases explained

Analytical look into recent insider purchases

Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

$IMMX Press Releases

Fastest customizable press release news feed in the world

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

$IMMX Large Ownership Changes

This live feed shows all institutional transactions in real time.

$IMMX SEC Filings

SEC Form SC 13G filed by Immix Biopharma Inc.

SEC Form SC 13D filed by Immix Biopharma Inc.

SEC Form SC 13G/A filed by Immix Biopharma Inc. (Amendment)

SEC Form 10-Q filed by Immix Biopharma Inc.

Immix Biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Immix Biopharma Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

$IMMX Leadership Updates

Live Leadership Updates

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

$IMMX Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target

Immix Biopharma Doses First Patient In U.S. AL Amyloidosis Trial With CAR-T NXC-201; Data From ex-US Clinical Trial Reported At ASGCT 2024 Showed A 92% Overall Response Rate

HC Wainwright & Co. Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $7

$IMMX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Hsu Jason bought $51,623 worth of shares (23,100 units at $2.23), increasing direct ownership by 3% to 845,300 units (SEC Form 4)

Director Ng Carey bought $18,600 worth of shares (10,000 units at $1.86), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

Director Hsu Jason bought $19,517 worth of shares (9,200 units at $2.12), increasing direct ownership by 1% to 822,200 units (SEC Form 4)

$IMMX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Hsu Jason bought $51,623 worth of shares (23,100 units at $2.23), increasing direct ownership by 3% to 845,300 units (SEC Form 4)

Director Ng Carey bought $18,600 worth of shares (10,000 units at $1.86), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

Director Hsu Jason bought $19,517 worth of shares (9,200 units at $2.12), increasing direct ownership by 1% to 822,200 units (SEC Form 4)

Recent Analyst Ratings for
$IMMX

$IMMX
Insider purchases explained

$IMMX
Press Releases

$IMMX
Large Ownership Changes

$IMMX
SEC Filings

$IMMX
Leadership Updates

$IMMX
Market Insights

$IMMX
Insider Purchases

$IMMX
Insider Trading